$4 million grant from Mirati Therapeutics to support SU2C research on KRAS mutant cancers

(Stand Up To Cancer) Stand Up To Cancer® (SU2C) and Mirati Therapeutics Inc. (NASDAQ: MRTX) - a late-stage targeted oncology company - announce that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.